# LSM2

## Overview
LSM2 is a gene that encodes a protein involved in critical cellular processes related to RNA metabolism. The LSM2 protein is a component of the LSM2-8 complex, which plays a pivotal role in RNA processing, particularly in the splicing of mRNA precursors and the stabilization of U6 small nuclear RNA (snRNA) within the nucleus (Sun2023LSM2; Sun2022Expression). Additionally, LSM2 is part of the LSM1-7 complex in the cytoplasm, where it contributes to mRNA decapping, a key step in mRNA degradation and turnover (Wu2013Lsm2). The protein is characterized by its participation in forming hetero-heptameric ring structures, which are essential for its function in RNA binding and processing (Wu2013Lsm2). Beyond its fundamental biological roles, LSM2 has been implicated in various cancers, where its expression levels are associated with disease progression and prognosis, highlighting its potential as a biomarker and therapeutic target (Sun2023LSM2; Ta2021Potential).

## Structure
The LSM2 protein is part of the Lsm2-3-Pat1C complex, forming a hetero-heptameric ring structure with a central cavity. This heptamer consists of four Lsm3 proteins and three Lsm2 proteins, creating an asymmetrical interaction network with six Lsm2/Lsm3 interfaces and one Lsm3/Lsm3 interface (Wu2013Lsm2). Each Lsm protein, including LSM2, contains a conserved Sm fold, characterized by an N-terminal α helix followed by a highly bent five-stranded β sheet. The C-terminal extension of Lsm2 forms a second α helix (Wu2013Lsm2).

The Lsm2-3-Pat1C complex has a doughnut shape with two faces, the helix and loop faces, and a central cavity connecting them. The outer diameter at the helix face is approximately 60 Å, while the loop face is about 26 Å, with an inner diameter of 19 Å at its narrowest part and a thickness of 42 Å (Wu2013Lsm2). The interaction between the C-terminal domain of Pat1 and the C-terminal helix of Lsm2 is essential for the complex's function, contributing to negatively charged patches on the loop face that may affect RNA binding (Wu2013Lsm2).

## Function
The LSM2 gene encodes a protein that is a component of the LSM2-8 complex, which plays a crucial role in RNA processing within healthy human cells. This complex is involved in the splicing of mRNA precursors by participating in the spliceosomal cycle, a process essential for the regulation of gene expression (Sun2022Expression). The LSM2-8 complex is located in the nucleus, where it stabilizes U6 small nuclear RNA (snRNA) and promotes RNA decay, contributing to RNA stability and processing (Sun2023LSM2; Montemayor2020Molecular).

The LSM2-8 complex binds the 3′ ends of U6 and U6 atac snRNAs, facilitating their processing by the 3′-5′ exoribonuclease Usb1, which results in a 2′, 3′ cyclic phosphate, a modification crucial for RNA stability (Montemayor2020Molecular; Sun2022Expression). This complex also interacts with telomerase RNA and other RNA sequences, indicating its role in various RNA processing pathways (Montemayor2020Molecular).

In addition to its nuclear functions, LSM2 is part of the LSM1-7 complex in the cytoplasm, where it is involved in mRNA decapping, a critical step in mRNA degradation and turnover (Sun2023LSM2; Wu2013Lsm2). This dual role in RNA splicing and degradation highlights LSM2's importance in maintaining normal cellular functions and gene expression regulation.

## Clinical Significance
LSM2 has been implicated in several cancers due to its altered expression levels and potential role in disease progression. In breast cancer (BRCA), LSM2 is overexpressed in tumor tissues compared to normal tissues, with its expression correlating with advanced tumor stages and poor recurrence-free survival (RFS) prognosis. This suggests that LSM2 could serve as a biomarker for early detection and prognosis in BRCA (Ta2021Potential). 

In skin cutaneous melanoma (SKCM), LSM2 is associated with poor overall survival (OS) and disease-free survival (DFS). High expression levels of LSM2 in SKCM tissues are linked to shorter survival times and early recurrence, indicating its potential as a prognostic biomarker and therapeutic target (Sun2023LSM2). 

In liver hepatocellular carcinoma (LIHC), LSM2 is highly expressed and correlates with poor prognosis, including lower OS and DFS rates. Knockdown experiments have shown that reducing LSM2 expression inhibits cell proliferation, migration, and invasion, highlighting its role in cancer progression and its potential as a therapeutic target (Qin2023The). 

These findings underscore the clinical significance of LSM2 in various cancers, suggesting its involvement in tumor progression and its potential utility in cancer diagnosis and treatment strategies.

## Interactions
LSM2 is a component of the Lsm2-3-Pat1C complex, where it forms a hetero-heptameric ring structure with Lsm3, consisting of four Lsm3 proteins and three Lsm2 proteins. This complex interacts with Pat1C, which is composed of 15 α helices forming a right-handed α-α superhelix domain. The N-terminal region of Pat1C associates with the Lsm2-3 heptameric ring through helix-helix interactions (Wu2013Lsm2). LSM2, along with Lsm3, plays a crucial role in bridging the interaction between the Lsm1-7 complex and Pat1, which is essential for decapping activation. This interaction involves the C-terminal domain of Pat1 with the C-terminal helix of Lsm2 and the N-terminal helix of Lsm3 (Wu2013Lsm2).

LSM2 is also part of the LSm2-8 protein ring, which stabilizes the U6 snRNA and is involved in spliceosome activation. During this process, LSm2-8 is released, which is crucial for the creation of the active site for pre-mRNA splicing. The LSm ring forms a ternary complex with U6 and U2 RNAs, indicating it may stabilize U2/U6 helix II during activation (Kaur2019Function). LSM2 interacts with several proteins, including Pat1, Psu1, and Yel015w, suggesting a connection to the mRNA degradation pathway (FromontRacine2000GenomeWide).


## References


1. (Montemayor2020Molecular) Molecular basis for the distinct cellular functions of the Lsm1-7 and Lsm2-8 complexes. This article has 1 citations.

[2. (Qin2023The) Peifang Qin, Haitao Huang, Jiahui Wang, Tingting Jiang, Nannan Zeng, Qi Wang, Yulin He, and Yali Zhou. The mechanism of lsm2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics. Medical Oncology, August 2023. URL: http://dx.doi.org/10.1007/s12032-023-02152-0, doi:10.1007/s12032-023-02152-0. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12032-023-02152-0)

[3. (Sun2023LSM2) Xiaofang Sun, Jianping Zhang, Jiayuan Hu, Qingdong Han, and Zili Ge. Lsm2 is associated with a poor prognosis and promotes cell proliferation, migration, and invasion in skin cutaneous melanoma. BMC Medical Genomics, June 2023. URL: http://dx.doi.org/10.1186/s12920-023-01564-1, doi:10.1186/s12920-023-01564-1. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-023-01564-1)

[4. (Wu2013Lsm2) Donghui Wu, Denise Muhlrad, Matthew W Bowler, Shimin Jiang, Zhou Liu, Roy Parker, and Haiwei Song. Lsm2 and lsm3 bridge the interaction of the lsm1-7 complex with pat1 for decapping activation. Cell Research, 24(2):233–246, November 2013. URL: http://dx.doi.org/10.1038/cr.2013.152, doi:10.1038/cr.2013.152. This article has 43 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/cr.2013.152)

[5. (FromontRacine2000GenomeWide) Micheline Fromont-Racine, Andrew E. Mayes, Adeline Brunet-Simon, Jean-Christophe Rain, Alan Colley, Ian Dix, Laurence Decourty, Nicolas Joly, Florence Ricard, Jean D. Beggs, and Pierre Legrain. Genome-wide protein interaction screens reveal functional networks involving sm-like proteins. Yeast, 1(2):95–110, 2000. URL: http://dx.doi.org/10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H, doi:10.1002/1097-0061(20000630)17:2<95::aid-yea16>3.0.co;2-h. This article has 284 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/1097-0061(20000630)17:2)

[6. (Ta2021Potential) Hoang Dang Khoa Ta, Wei-Jan Wang, Nam Nhut Phan, Nu Thuy An Ton, Gangga Anuraga, Su-Chi Ku, Yung-Fu Wu, Chih-Yang Wang, and Kuen-Haur Lee. Potential therapeutic and prognostic values of lsm family genes in breast cancer. Cancers, 13(19):4902, September 2021. URL: http://dx.doi.org/10.3390/cancers13194902, doi:10.3390/cancers13194902. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13194902)

[7. (Sun2022Expression) Xiaofang Sun, Jianping Zhang, Can Xiao, and Zili Ge. Expression profile and prognostic values of lsm family in skin cutaneous melanoma. BMC Medical Genomics, November 2022. URL: http://dx.doi.org/10.1186/s12920-022-01395-6, doi:10.1186/s12920-022-01395-6. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-022-01395-6)

[8. (Kaur2019Function) Harpreet Kaur, Margaret L. Rodgers, and Aaron A. Hoskins. Function and dynamics of the lsm2-8 protein ring during spliceosome activation. Biophysical Journal, 116(3):356a, February 2019. URL: http://dx.doi.org/10.1016/j.bpj.2018.11.1936, doi:10.1016/j.bpj.2018.11.1936. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bpj.2018.11.1936)